The Depo-Provera lawsuit: who qualifies and what's known about meningioma risk
The Depo-Provera litigation just did something almost unheard of in mass torts: it reached a global settlement before a single trial, before the court ruled on the key scientific evidence, and barely 16 months after the cases were consolidated. On June 15, 2026, Judge M. Casey Rodgers entered an order confirming that Pfizer and the plaintiffs' leadership had reached a settlement in principle covering eligible claims in MDL 3140.
For the more than 5,800 women with pending federal cases, and the many others still evaluating claims, the announcement changes the landscape without yet answering the questions that matter most: how much, who exactly qualifies, and what happens to everyone outside the deal. Here is where the litigation stands and what the settlement does and doesn't resolve.
What is the Depo-Provera lawsuit about?
The lawsuits allege that Pfizer's injectable contraceptive Depo-Provera (medroxyprogesterone acetate, or MPA) causes meningioma brain tumors with long-term use, and that Pfizer knew or should have known about the risk for decades but failed to warn U.S. patients and doctors. Meningiomas are tumors of the membranes surrounding the brain; they are usually non-cancerous but can require brain surgery or radiation, cause vision loss, seizures, and neurological damage, and demand lifelong monitoring even when untreated.
The failure-to-warn allegation has a specific sting: Pfizer added meningioma warnings to Depo-Provera labels in other countries years before any U.S. warning existed. The U.S. label did not warn of meningioma risk until the FDA approved updated labeling in December 2025, decades after the first scientific signals appeared and more than a year into the litigation itself. The updated label now instructs that patients be monitored for meningioma symptoms and that the drug be discontinued if a meningioma is diagnosed.
What does the science show?
Two major studies anchor the plaintiffs' causation case. The first, published in The BMJ in 2024, analyzed French national health data covering more than 18,000 women who underwent surgery for intracranial meningioma. Women who had used injectable medroxyprogesterone acetate for more than one year showed approximately 5.5 times the odds of developing meningioma compared to non-users. Other hormonal contraceptives did not show the same risk.
The second, a 2025 study in JAMA Neurology examining tens of millions of U.S. patient records, confirmed the signal: women who used DMPA had roughly twice the risk of meningioma diagnosis compared to women not on hormonal birth control, with risk concentrated in longer-duration users and women over 31.
The biological mechanism has been studied far longer. Research dating to 1983 identified high concentrations of progesterone receptors in meningioma cells, and progesterone's role in stimulating meningioma growth is well documented; medroxyprogesterone acetate is a potent synthetic progestin delivered at contraceptive doses four times a year.
Where does MDL 3140 stand?
The Judicial Panel on Multidistrict Litigation consolidated the federal cases on February 7, 2025, in the Northern District of Florida before Judge M. Casey Rodgers, the same judge who managed the 3M earplug litigation, the largest MDL in history. Judge Rodgers moved the docket fast: direct filing into the MDL was authorized by March 2025, leadership was appointed, monthly case management conferences were set, five bellwether pilot cases were selected, and the first trial was scheduled for December 7, 2026.
The docket grew explosively. From 73 cases at consolidation, filings reached roughly 2,100 by February 2026, 3,790 by March, and then surged by more than 1,700 new cases in June 2026 alone (the largest single-month jump in the MDL's history, driven by attorneys racing to file before any settlement eligibility cutoff). As of the July 2026 JPML report, 6,294 cases were pending of 5,916 total filed, making this one of the ten largest active litigations in the country.
Then came the settlement. On June 15, 2026, Judge Rodgers confirmed that plaintiffs' lead counsel and defendants Pfizer, Pharmacia LLC, and Pharmacia & Upjohn had reached a global agreement in principle. The order vacated the December bellwether trial deadlines and reset the general-causation Daubert hearing to July 27, 2026.
Why is the early settlement so unusual?
Mass torts almost never settle this early. The standard arc runs years: consolidation, discovery, expert challenges, bellwether trials, and only then, with verdict data pressuring both sides, a global deal. The hernia mesh litigation took the full path: eight years from consolidation to its 2024 settlement. The Depo-Provera agreement came before the court ruled on Pfizer's federal-preemption motion, before the Daubert ruling on whether plaintiffs' experts could testify at all, and before any jury heard any case.
The early resolution suggests both sides saw serious risk. For Pfizer: strong published science, an FDA label change that undercut its preemption defense (the argument that the FDA had prevented it from warning), a docket growing by four figures monthly, and a judge with a record of moving mass torts to trial on schedule. For plaintiffs: preemption remained a live threat that could have gutted the failure-to-warn claims entirely, and a Daubert loss would have ended the litigation. Settlement before either ruling let both sides avoid their catastrophic scenario.
Who qualifies, and what about cases outside the deal?
The settlement's eligibility criteria, payment structure, and total amount have not been made public; the parties are still memorializing terms. What the June 15 order establishes: the agreement covers eligible plaintiffs with cases pending in the federal MDL, it will not resolve every case, and it does not affect state-court filings (active dockets exist in Pennsylvania, California, and Illinois).
The general qualification profile from the litigation itself: use of Depo-Provera, Depo-SubQ Provera 104, or an authorized generic (most firms screened for two or more injections), a meningioma diagnosis confirmed by imaging such as MRI, no prior brain-tumor history, and a claim within the state statute of limitations (typically one to three years from diagnosis, with discovery-rule extensions in many states). Cases involving surgical removal or radiation treatment are generally valued above monitoring-only cases in any tiered settlement structure, following the pattern of every pharmaceutical mass tort.
For claims outside the settlement, the litigation machinery continues: the July 27 Daubert hearing remains on calendar precisely because general causation must still be resolved for non-settling and future cases, and the state-court tracks proceed independently.
What should potential claimants do now?
If you used Depo-Provera long-term and have been diagnosed with a meningioma, the settlement announcement makes prompt action more important, not less. Settlement programs have eligibility cutoffs, and the June filing surge happened because attorneys understand that late claims risk exclusion.
Gather the two record sets that determine everything: proof of use (pharmacy records, prescription histories, or medical records documenting the injections and their dates) and proof of injury (the imaging report confirming the meningioma diagnosis, plus any treatment records for surgery or radiation).
Then get a case evaluation from a mass-tort attorney. Consultations are free and representation is contingency-based. The attorney can determine whether your claim fits the settlement's eligibility (once terms are public), whether filing into the MDL or a state court is the better path, and whether your state's limitations period is still open. The statute of limitations analysis in mass-tort cases turns on when you connected the diagnosis to the product, which is a fact-specific question worth professional review rather than self-assessment.
If you used Depo-Provera and have symptoms but no diagnosis (persistent headaches, vision changes, hearing loss, seizures), the medical step precedes the legal one: the December 2025 label change specifically directs monitoring for meningioma symptoms, and an MRI is the diagnostic tool. A diagnosis, not symptoms alone, is what supports a claim.
The Depo-Provera litigation will be studied for years as the mass tort that resolved at unprecedented speed. For the women involved, the next milestones are concrete: the settlement terms becoming public, the claims process opening, and the July 27 hearing that shapes everything outside the deal.